May 31, 2022

How Can We Investigate Biomarkers For Lung Cancer Patients More Effectively?

March 22, 2021

Revealing the Blind Spot in Cancer Treatment with Host Response Profiling

January 13, 2021

Treating cancer with precision: It’s time for host response profiling

February 13, 2020

Cancer Therapy in 2020: The promise of host-response profiling

March 5, 2024

OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

October 31, 2023

OncoHost to Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients at SITC 2023

October 23, 2023

Journal of Pharmaceutical & Biomedical Analysis Publishes Study Analytically Validating OncoHost's PROphet® Test as a Decision Support Tool for Metastatic NSCLC Patients

October 3, 2023

OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer

May 25, 2023

OncoHost to Present PROphet® Biomarker Model that Accurately Predicts Clinical Benefit to ICI-Based Treatment at ASCO 2023

May 4, 2023

OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech

February 1, 2023

OncoHost Launches PROphet® NSCLC Test in the United States

January 11, 2023

OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform

January 10, 2023

Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer

November 7, 2022

OncoHost to Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022

October 3, 2022

OncoHost Announces New Executive Appointments Ahead of Imminent Launch of its Precision Oncology Platform

June 21, 2022

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients